What is the Need for Prostatic Biomarkers in Prostate Cancer Management? (Q26798425)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

What is the Need for Prostatic Biomarkers in Prostate Cancer Management? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

1 reference

3 April 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Martin Spahn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Silvan Boxler

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Marco Moschini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Bertrand Tombal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

R Jeffrey Karnes

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

1 October 2015

2 references

3 April 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

published in

Current urology reports

3 references

3 April 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

22 February 2020

copyright license

1 reference

on focus list of Wikimedia project

3 April 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Increased survival with enzalutamide in prostate cancer after chemotherapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

The mutational landscape of lethal castration-resistant prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Integrative genomic profiling of human prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Tracking the clonal origin of lethal prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Is PTEN loss associated with clinical outcome measures in human prostate cancer?

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Spatial genomic heterogeneity within localized, multifocal prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Integrative clinical genomics of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4534510

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26267226

12 December 2020

inferred from PubMed ID database lookup

Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26267226

12 December 2020

inferred from PubMed ID database lookup

European perspective for effective cancer drug development

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

7 January 2021

inferred from DOI database lookup

Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0545-3

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1007/S11934-015-0545-3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

22 February 2020

1008997264

0 references

Fatcat ID

release_z644mhxlrvhh7iuy5f6mgipna4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/z644mhxlrvhh7iuy5f6mgipna4

24 November 2022

mapped directly with Wikidata item

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

26267226

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26267226%20AND%20SRC:MED&resulttype=core&format=json